American Heart Journal
Volume 156, Issue 6 , Pages 1133-1140 , December 2008

Disparity in drug-eluting stent utilization by insurance type

  • John Kao, MD

      Affiliations

    • University of Illinois at Chicago, Chicago, IL
    • Corresponding Author InformationReprint requests: John Kao, MD, University of Illinois at Chicago, Division of Cardiology, 840 S. Wood Street Suite 926, M/C 715, Chicago, IL 60612.
    • ,
  • Ricardo Vicuna, MD

      Affiliations

    • University of Illinois at Chicago, Chicago, IL
    • ,
  • John A. House, MS

      Affiliations

    • Mid America Heart Institute of St. Luke's Hospital and University of Missouri-Kansas City, Kansas City, MO
    • ,
  • John S. Rumsfeld, MD, PhD

      Affiliations

    • Denver Veterans Affairs Medical Center and the University of Colorado, Denver, CO
    • ,
  • Henry H. Ting, MD, MBA

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
    • ,
  • John A. Spertus, MD

      Affiliations

    • Mid America Heart Institute of St. Luke's Hospital and University of Missouri-Kansas City, Kansas City, MO
    • ,
  • on behalf of the National Cardiovascular Data CathPCI Registry (NCDR)

Received 13 July 2007 ,Accepted 10 July 2008.

References 

  1. Morice MC, Serruys PW, Sousa JE, et al. and RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  2. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  5. Hodgson JM, Bottner RK, Klein LW, et al. Drug-eluting stent task force: Final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheter Cardiovasc Interv. 2004;62:1–17
  6. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to?. J Am Coll Cardiol. 2004;43:513–518
  7. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation. 2006;114:1736–1743discussion 44
  8. Kong DF, Eisenstein EL, Sketch MH, et al. Economic impact of drug-eluting stents on hospital systems: A disease-state model. Am Heart J. 2004;147:449–456
  9. O’Neill WW, Leon MB. Drug-eluting stents: Costs versus clinical benefit. Circulation. 2003;107:3008–3011
  10. Holmes DR, Firth BG, Wood DL. Paradigm shifts in cardiovascular medicine. J Am Coll Cardiol. 2004;43:507–512
  11. Sada MJ, French WJ, Carlisle DM, et al. Influence of payor on use of invasive cardiac procedures and patients outcome after myocardial infarction in the United Sates. J Am Coll Cardiol. 1998;31:1474–1480
  12. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors and outcomes of drug-eluting stent utilization in patients with high-risk non–ST segment elevation acute coronary syndromes. Am J Cardiol. 2005;96:750–755
  13. Wenneker MB, Weissman JS, Epstein AM. The association of payer with utilization of cardiac procedures in Massachusetts. JAMA. 1990;264:1255–1260
  14. Langa KM, Sussman EJ. The effects of cost-containment policies on rates of coronary revascularization in California. N Engl J Med. 1993;329:1784–1789
  15. Carlisle DM, Siu AL, Keeler KB, et al. HMO vs fee-for-service care of older persons with acute myocardial infarction. Am J Public Health. 1992;82:1626–1630
  16. Hadley J, Steinberg E, Feder J. Comparison of uninsured and privately insured hospital patients: condition on admission, resources use and outcomes. JAMA. 1991;265:374–379
  17. The Institute of Medicine report . Unequal treatment: confronting racial and ethnic disparities in health care. Washington DC: National Academy Press; 2002;
  18. US Department of Health and Human Services . Healthy people 2010. Available at www.health.gov/healthypeopleLast accessed September 16, 2008
  19. Every NR, Cannon CP, Granger C, et al. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry. J. Am. Coll. Cardiol. 1998;32:387–392
  20. Bakhai A, Shi C, Githiora L, et al. Cost-effectiveness of SES for treatment of complex coronary stenoses. Circulation. 2004;110:508–514
  21. van Hout BA, Lindeboom WK, Morice MC, et al. Cost-effectiveness of the sirolimus eluting bx-VELOCITY stent: 1-year results. Eur Heart J. 2002;23(Suppl):691
  22. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: results from the randomized SIRIUS trial (abstr). J Am Coll Cardiol. 2003;41(Suppl):32A
  23. Weintrab WS, McKay CR, Riner RN, et al. The American College of Cardiology National Database: progress and challenges. J Am Coll Cardiol. 1997;29:459–465
  24. Brindis RG, Fitzgerald S, Anderson HV, et al. The American College of Cardiology—National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37:2240–2245
  25. Cox JL, Chen E, Naylor CD. Revascularization after acute myocardial infarction: impact of hospital teaching status and on-site invasive facilities. J Gen Intern Med. 1994;9:674–678
  26. Alter DA, Naylor CD, Austin P, et al. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359–1367
  27. Thiemann DR, Coresh J, Oetgen WJ, et al. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med. 1999;340:1640–1648
  28. Eisenberg JM, Power EJ. Transforming insurance coverage into quality healthcare; voltage drops from potential to delivered quality. JAMA. 2000;284:2100–2107
  29. Rahimi AR, Spertus JA, Reid KJ, et al. Financial barriers to healthcare and outcomes after acute myocardial infarction. JAMA. 2007;297:1063–1072
  30. Calvin JE, Roe MT, Chen AY, et al. Insurance coverage and care of patients with non-st-segment elevation acute coronary syndromes. Ann Intern Med. 2006;145:739–748
  31. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial. Circulation. 2004;110:508–514
  32. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:253–261
  33. Ong ATL, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. European Heart Journal. 2006;27:2996–3003
  34. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet. 2005;366:921–929
  35. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEff ektivitäts Trial (BASKET): an 18-month analysis. Lancet. 2007;370:1552–1559
  36. Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J. 2006;152:321–326
  37. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  38. Lagerqvist B, James SK, Stenestrand U, et al. for the SCAAR Study Group Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  39. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:10309
  40. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  41. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393–1402
  42. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER Registry. Circulation. 2006;113:2803–2809
  43. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation. 2007;115:813–818
  44. Shields AE. Trends in private insurance, Medicaid/State Children's Health Insurance Program, and the Health-Care Safety Net: implications for asthma disparities. Chest. 2007;132:818–830
  45. Galbraith AA, Wong ST, Kim SE, et al. Out-of-pocket financial burden for low-income families with children: socioeconomic disparities and effects of insurance. Health Serv Res. 2005;40:1722–1736

PII: S0002-8703(08)00629-7

doi: 10.1016/j.ahj.2008.07.012

American Heart Journal
Volume 156, Issue 6 , Pages 1133-1140 , December 2008

Article Tools

* Image Usage & Resolution